JETO HomeIssue Contents

Nedaplatin and irinotecan for patients with recurrent small cell lung cancer
Miki Ohe, Fumihiro Oshita, Yoshiyuki Kenmotsu, Makiko Sugiura, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito and Kouzo Yamada

Background: No standard second-line combination chemotherapy has yet been established for patients with recurrent small cell lung cancer (RSCLC).

Methods: Patients with RSCLC were treated with nedaplatin (NP) at 50 mg/m2 and irinotecan (CPT) at 50 mg/m2 on days 1 and 8 every 4 weeks for four cycles.

Results: The clinical outcomes of 12 patients (9 male and 3 female; age range 48–76 years, median 62 years) were retrospectively analyzed. Seven of the patients showed sensitive relapse. Two patients had a performance status of 2. Nine of the patients were able to receive 4 to 6 courses of NP and CPT chemotherapy. Grade 3 or 4 anemia, neutropenia and thrombocytopenia occurred in 25.0%, 50.0% and 41.7% of patients, respectively. There were no grade 3 or 4 non-hematologic toxicities except for febrile neutropenia in 1 patient. There was no treatment-related death. Nine patients achieved PR, and the objective response rate was 75.0%. The median survival time was 11.1 months (range 4.8 to 31.3+ months) and the 1-year survival rate was 50.0%.

Conclusion: NP and CPT in combination are effective and safe for patients with RSCLC.

Keywords: lung cancer, small cell, nedaplatin, irinotecan

Full Text (IP)